Skip to main content

Treatment of hyperprolactinemia in post-menopausal women: pros

Abstract

The incidence of hyperprolactinemia in women peaks during the 3rd–4th decade and then greatly decreases after the menopause. Apart from the effects on the hypothalamic–pituitary–gonadal axis, prolactin can act directly on bone metabolism. Hyperprolactinemia is a recognized cause of secondary osteoporosis, and treatment with dopamine agonists can lead to improved BMD. Moreover, hyperprolactinemia has been linked to weight gain and insulin resistance, which can be ameliorated following medical treatment. Although relatively rare, prolactinomas can be observed in post-menopausal women and are frequently large and invasive; dopamine agonists appear to be as effective in these patients as in younger women to induce reduction of prolactin levels and tumour shrinkage. Here, we review data potentially favouring medical treatment with dopamine agonists in post-menopausal women diagnosed with hyperprolactinemia.

This is a preview of subscription content, access via your institution.

References

  1. T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am. 37(1), 67–99 (2008)

    Article  CAS  PubMed  Google Scholar 

  2. M. Kars, P.C. Souverein, R.M. Herings et al., Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J. Clin. Endocrinol. Metab. 94(8), 2729–2734 (2009)

    Article  CAS  PubMed  Google Scholar 

  3. M.E. Lieberman, R.A. Maurer, P. Claude, J. Gorski, Prolactin synthesis in primary cultures of pituitary cells: regulation by estradiol. Mol. Cell. Endocrinol. 25(3), 277–294 (1982)

    Article  CAS  PubMed  Google Scholar 

  4. S. Karunakaran, R.C. Page, J.A. Wass, The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin. Endocrinol. 54(3), 295–300 (2001)

    Article  CAS  Google Scholar 

  5. V. Dos Santos Nunes, R. El Dib, C.L. Boguszewski, C.R. Nogueira, Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 14(3), 259–265 (2011)

    Article  PubMed  Google Scholar 

  6. M.E. Molitch, Pituitary tumors: cabergoline versus bromocriptine: a meta-analysis? Nat. Rev. Endocrinol. 7(5), 254–255 (2011)

    Article  CAS  PubMed  Google Scholar 

  7. A. Colao, A. Di Sarno, M.L. Landi et al., Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J. Clin. Endocrinol. Metab. 85(6), 2247–2252 (2000)

    CAS  PubMed  Google Scholar 

  8. F.F. Casanueva, M.E. Molitch, J.A. Schlechte et al., Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65(2), 265–273 (2006)

    Article  Google Scholar 

  9. S. Melmed, F.F. Casanueva, A.R. Hoffman et al., Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(2), 273–288 (2011)

    Article  CAS  PubMed  Google Scholar 

  10. L. Vroonen, M.L. Jaffrain-Rea, P. Petrossians et al., Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur. J. Endocrinol. 167(5), 651–662 (2012)

    Article  CAS  PubMed  Google Scholar 

  11. E. Delgrange, G. Raverot, M. Bex et al., Giant prolactinomas in women. Eur. J. Endocrinol. 170(1), 31–38 (2014)

    Article  CAS  PubMed  Google Scholar 

  12. I. Shimon, M.D. Bronstein, J. Shapiro, G. Tsvetov, C. Benbassat, A. Barkan, Women with prolactinomas presented at the postmenopausal period. Endocrine. (2014). doi:10.1007/s12020-014-0259-1

  13. G. Mazziotti, T. Mancini, M. Mormando et al., High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14(4), 299–306 (2011)

    Article  CAS  PubMed  Google Scholar 

  14. D. Seriwatanachai, N. Krishnamra, J.P. van Leeuwen, Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization. J. Cell. Biochem. 107(4), 677–685 (2009)

    Article  CAS  PubMed  Google Scholar 

  15. D. Seriwatanachai, K. Thongchote, N. Charoenphandhu et al., Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone 42(3), 535–546 (2008)

    Article  CAS  PubMed  Google Scholar 

  16. A. Klibanski, S.L. Greenspan, Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. 315(9), 542–546 (1986)

    Article  CAS  PubMed  Google Scholar 

  17. J. Schlechte, G. el-Khoury, M. Kathol, L. Walkner, Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J. Clin. Endocrinol. Metab. 64(5), 1021–1026 (1987)

    Article  CAS  PubMed  Google Scholar 

  18. G. Mazziotti, T. Porcelli, M. Mormando et al., Vertebral fractures in males with prolactinoma. Endocrine. 39(3), 288–293 (2011)

    Article  CAS  PubMed  Google Scholar 

  19. A. Shibli-Rahhal, J. Schlechte, The effects of hyperprolactinemia on bone and fat. Pituitary 12(2), 96–104 (2009)

    Article  CAS  PubMed  Google Scholar 

  20. Y. Greenman, K. Tordjman, N. Stern, Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin. Endocrinol. 48(5), 547–553 (1998)

    Article  CAS  Google Scholar 

  21. C. Ling, L. Svensson, B. Oden et al., Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J. Clin. Endocrinol. Metab. 88(4), 1804–1808 (2003)

    Article  CAS  PubMed  Google Scholar 

  22. M. Doknic, S. Pekic, M. Zarkovic et al., Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur. J. Endocrinol. 147(1), 77–84 (2002)

    Article  CAS  PubMed  Google Scholar 

  23. A. Tuzcu, M. Bahceci, M. Dursun, C. Turgut, S. Bahceci, Insulin sensitivity and hyperprolactinemia. J. Endocrinol. Invest. 26(4), 341–346 (2003)

    Article  CAS  PubMed  Google Scholar 

  24. S.S. Inancli, A. Usluogullari, Y. Ustu et al., Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine 44(1), 193–199 (2013)

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have nothing to disclose and did not receive any Grant supporting the writing of this paper.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D. Iacovazzo.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Iacovazzo, D., De Marinis, L. Treatment of hyperprolactinemia in post-menopausal women: pros. Endocrine 48, 76–78 (2015). https://doi.org/10.1007/s12020-014-0377-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-014-0377-9

Keywords

  • Hyperprolactinemia
  • Menopause
  • Dopamine agonists